{ "Study of Obicetrapib and Repatha for High Lp(a)", "This study is looking at how two medications, obicetrapib and evolocumab (also known as Repatha), affect levels of lipoprotein(a) or Lp(a). Lp(a) is a type of cholesterol that can increase your risk of heart disease. You may be able to join if you are between 18 and 75 years old and have high Lp(a) levels (at least 20 mg/dL or 50 nmol/L) and certain other cholesterol levels. The main goal is to see how much Lp(a) levels change after 8 weeks of taking obicetrapib daily along with evolocumab every two weeks. The study is currently unclear about its recruitment status and plans to enroll 69 participants.", "design": "This is an open-label study, meaning you and your doctors will know which medications you are receiving. It plans to enroll 69 participants to evaluate the effects of the medications.", "commitments": "You would have your Lp(a) tested at the start, take obicetrapib daily for 8 weeks, have Lp(a) retested, then take obicetrapib daily and evolocumab every two weeks for another 8 weeks, and have Lp(a) retested again.", "compensation": "Not stated in the trial record.", "follow_up": "Your Lp(a) levels will be measured at 16 weeks from the start of the study, after 8 weeks on the combination therapy.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.